Metis Pharmaceuticals is a cutting-edge biotech startup that leverages advanced technologies such as Artificial Intelligence (AI), Machine Learning (ML), and Molecular Dynamics (MD) to revolutionize drug discovery and development. The company operates in the pharmaceutical industry, specifically in the development of novel therapeutics in the small molecule, biologics, and advanced nucleic acid spaces.

The company's business model is centered around the use of AI and high-throughput in vivo screening to discover unique Lipid Nanoparticles (LNPs) with world-class capabilities. LNPs are tiny particles used to deliver drugs to specific parts of the body. Metis' LNPs have shown high delivery efficiency and clean safety profiles, targeting multiple organ systems in animal models.

Metis Pharmaceuticals also aims to build a proprietary predictive AI platform to redefine drug discovery. This platform will help in creating a robust and targeted delivery system for small molecules, RNA, and gene therapies. The ultimate goal is to provide clinical value to patients by exploring the uncharted territory of AI and the new biology.

The company is open to partnerships focused on their novel AI- and ML-developed nanoparticles. This indicates a potential revenue stream through strategic collaborations and partnerships with other companies or research institutions.

In summary, Metis Pharmaceuticals is a promising startup in the biotech space, using AI and ML to innovate drug discovery and development, with a focus on LNPs.

Keywords: Biotech, Artificial Intelligence, Machine Learning, Molecular Dynamics, Drug Discovery, Lipid Nanoparticles, Small Molecules, Biologics, Advanced Nucleic Acid, Partnerships.